Articles tagged with Vaccine Development
A recent study has found that potential COVID-19 vaccines are not affected by the dominant 'G-strain' of the virus. The G-strain now accounts for about 85 per cent of published SARS-CoV-2 genomes, but vaccine candidates targeting the spike protein remain effective. This discovery is good news for the hundreds of vaccines in development...
The Vaccination Game, developed by University of Oxford researchers, challenges players to deploy limited doses of a virtual vaccine to control the spread of a disease modelled on influenza. By replaying the game, players can improve their strategy and save more lives.
A team of scientists has developed a unique COVID-19 vaccine that utilizes a bovine adenovirus as a safe and effective delivery vehicle. The vaccine aims to provide protection to all segments of the population, especially older adults with declining immune systems.
A survey of 28 experts in vaccinology predicts that a publicly available COVID-19 vaccine may not be available before the fall of 2021. The majority of experts believe that the best-case scenario is a vaccine becoming available next summer, with some predicting it may take until 2022.
A West Virginia University professor argues that effective communication is crucial for gaining the American public's trust in scientists. By considering four dimensions of trust and tailored communication objectives, science communicators can increase perceptions of competence, integrity, benevolence, and openness.
A new CRISPR vaccine has been successfully tested in animal studies, providing protection against the parasitic skin disease leishmaniasis. The vaccine uses a modified version of the parasite that causes the disease, which induces immunity without causing clinical disease.
The University of Montana has received a five-year, $33.4 million award from the National Institutes of Health to develop and conduct clinical trials for opioid vaccines. The UM vaccine research team will advance lead opioid vaccine candidates to Phase I human clinical trials with funding from the NIH HEAL Initiative.
A new study confirms the safety and immunogenicity of the Vi-DT conjugate vaccine in children aged 6-23 months. The single-dose regimen shows anti-Vi seroconversion rates similar to the two-dose schedule, offering a promising solution for increasing global vaccination stockpiles.
Researchers developed a polymer-nanoparticle hydrogel that allows sustained release of vaccine components, increasing potency and duration of immune responses in mice. The hydrogel boosts antibody production with a 1,000-fold higher affinity for antigens.
Researchers at West Virginia University are developing a vaccine to prevent Lyme disease, which affects over 300,000 Americans annually. The team aims to identify relevant antigens and target them in hopes of clearing the pathogen out, making it harder for it to change and evade the immune system.
The International Vaccine Institute (IVI) is preparing clinical trial sites for COVID-19 vaccine efficacy trials in four African and Asian countries with the support of the Bill & Melinda Gates Foundation. IVI aims to bolster in-country capacity by 4Q2020 to ensure these sites are prepared for efficacy trials.
Researchers have developed a tool called COVID-3D to monitor mutations in the COVID-19 virus, helping to inform vaccine and drug development. The tool uses genomic and protein information to aid researchers in identifying effective targets for new treatments.
A study of over 27,000 COVID-19 samples reveals low genetic variation in SARS-CoV-2, suggesting a single vaccine could combat global infections. This finding supports the development of a broadly protective vaccine against COVID-19, building on previous successes with other viruses.
Vaxine Pty Ltd is accelerating clinical testing of its COVAX-19 vaccine using Microsoft's AI for Health program. The company aims to collect and analyze trial data in real-time, reducing the traditional waiting period.
A new COVID-19 vaccine delivered via the nose produces a strong immune response in mice, preventing infection and sterilizing immunity. The vaccine uses adenovirus technology with mutations to stabilize the spike protein, allowing for a single dose to induce robust protection against COVID-19.
A new vaccine candidate has been developed for HHV-6B, a virus that causes exanthem subitum in infants. The vaccine targets the gH/gL/gQ1/gQ2 complex and induces strong immunity against the virus. Animal experiments have shown that the vaccine prevents HHV-6B infection and activates dendritic cells to induce innate immunity.
Researchers have developed a promising COVID-19 vaccine candidate using virus-like particles (VLPs) that mimic the native SARS-CoV-2 virus. The VLP platform has shown success in stimulating immune responses against other viruses like HPV and HepB.
Researchers are developing and testing technology for delivering vaccine doses via the skin using microneedles. This innovative approach aims to improve patient compliance and yield better health outcomes, with potential benefits including reduced burden on healthcare systems and increased accessibility for self-administration at home.
A single-shot COVID-19 vaccine developed at Beth Israel Deaconess Medical Center raised neutralizing antibodies and protected non-human primates against SARS-CoV-2. The vaccine uses adenovirus serotype 26 to deliver the SARS-CoV-2 spike protein, stimulating immune responses.
Researchers at UCalgary's Snyder Institute for Chronic Diseases have unlocked new insights into the regulation of immunity against chronic infectious diseases. The study found that immune responses thought to be non-protective are actually essential in regulating excessive inflammation, which can facilitate infection.
Researchers are working on experimental gene-based vaccines using harmless viruses or DNA/RNA to deliver genetic information to human cells. The technology is fast but largely unproven, and concerns remain about neutralization levels and safety. Multiple types of vaccines will likely be needed to ensure effective immunity.
Researchers at the Weizmann Institute of Science created artificial cells that produced viral parts, allowing for safe testing and development of diagnostic tools, drugs, and vaccines. The system consists of micrometer-sized compartments etched into a silicon chip, enabling controlled production of specific proteins.
Researchers at UC San Diego highlight nanotechnology's role in COVID-19 vaccine development, including peptide-based vaccines and molecular farming. The first candidates in clinical trials utilize novel nanotechnologies.
The National Institutes of Health has established a new clinical trials network to enroll thousands of volunteers in large-scale clinical trials testing various COVID-19 vaccines and monoclonal antibodies. The COVPN will leverage existing infrastructure and engage communities to secure participants for late-stage clinical trials.
Researchers from Innovation Center of NanoMedicine and Tokyo Metropolitan Institute of Medical Science are developing an mRNA vaccine with immunostimulatory adjuvant functionality. The technology uses smart nanomachines to produce vaccines efficiently and at a low cost, tackling the ongoing COVID-19 pandemic and potential future new co...
Researchers from WRAIR and partners discuss the need for controlled human infection models (CHIMs) to study SARS-CoV-2, but note they won't advance current vaccines. CHIMs could provide valuable insights into vaccine efficacy and the virus's progression within the body.
A Japanese task force aims to identify genetic factors contributing to COVID-19 severity and develop an effective mucosal vaccine. By analyzing patient samples, the team hopes to uncover unique genetic susceptibilities associated with Japanese populations.
The NIH ACTIV working group assesses practical considerations for using controlled human infection models to support SARS-CoV-2 vaccine development. The authors conclude that large, randomized trials are the fastest path forward for establishing vaccine safety and efficacy.
Scientists have developed a promising vaccine using HydroVax technology, conferring 83% immunity against Campylobacter-associated diarrhea. The vaccine targets a disease associated with infant growth stunting and malnutrition in developing countries, potentially improving the health of millions.
Researchers found that one flu strain, H3N2, can mutate relatively easily to escape broad-acting antibodies, while another strain, H1N1, is more difficult to evade. The study highlights the challenges involved in designing a universal flu vaccine and suggests that further research is needed to develop an effective treatment.
The current serotype of dengue virus in Singapore has the ability to transform its structure, evading the host's immune response and making vaccines and therapeutics less effective. This poses a significant challenge for developing effective treatments and preventing dengue infections.
Researchers at NJIT have developed a new coulometric mass spectrometric approach to quantify proteins, which could aid in discovering new therapeutic antibodies or biomarkers. The method is faster and more efficient than current methods, requiring less time-consuming preparation of synthesized standard material.
Researchers at UConn's CEVR have made a breakthrough in vaccine development for Mycoplasma pneumoniae, a common and difficult-to-treat pneumonia-causing pathogen. By identifying the cause of vaccine-enhanced disease (VED), they were able to develop a new vaccine formulation that eliminates safety concerns.
The EPIC atlas provides a comprehensive immune cell database to study the mechanisms of immunity and develop more effective treatments. It enables researchers to stratify and analyze data sets using artificial intelligence, accelerating vaccine development and identifying new therapeutic targets.
Researchers at Westmead Institute for Medical Research identified a unique subset of human cells involved in the immune response against hepatitis B. The discovery could lead to new treatments and improved vaccines for HBV infection.
Researchers at Politecnico di Milano develop cutting-edge models for studying SARS-CoV-2 infection, accelerating the discovery of antiviral drugs and vaccines. Innovative tools like 3D supports, microfluidic chambers, and intravital microscopy promise to replace traditional animal research.
A new partnering agreement will finance a multi-centre Phase 2/3 adaptive clinical trial in Colombia, Panama, and Thailand to assess the safety and immunogenicity of the BBV87 vaccine candidate. The investment aims to accelerate the development of an effective Chikungunya vaccine for equitable access.
Researchers argue that deliberate infection can be done ethically and speed up vaccine development, with safeguards in place. The study provides guidance for regulators and researchers on maximizing benefits and minimizing risks.
Researchers have developed a new imaging analysis pipeline called LaMDA, which enables machine learning and complex analyses on high-dimensional microscopy data. This can reveal and predict T-cellular states, providing valuable insights for drug testing, vaccine development, and expanding knowledge of T-cell biology.
Researchers at BIDMC developed prototype COVID-19 vaccines that induced neutralizing antibody responses and protected against SARS-CoV-2 in rhesus macaques. The studies also found that individuals who recovered from COVID-19 developed natural protective immunity against re-infection.
Scientists have discovered a strong immune response to SARS-CoV-2 in people who have recovered from COVID-19, which provides a benchmark for testing vaccine candidates. The study also found substantial cross-reactivity against common cold coronaviruses, suggesting potential preexisting immunity.
Researchers are developing a vaccine targeting the spike protein, aiming to establish an immune response that protects against SARS-CoV-2 infection. The partnership with Tonix Pharmaceuticals accelerates the process, leveraging their expertise in product development.
The prevention of polio epidemics is a signature success of science in the 20th century. A new vaccine developed by Jonas Salk and later improved upon by Albert Sabin helped eradicate polio in the West, with the disease no longer a serious threat.
Researchers at Baylor College of Medicine are developing coronavirus vaccines using their years of experience in tropical diseases. They highlight experimental evidence showing the challenges and critical points for vaccine development, including the need for a robust antibody response and balanced cellular immunity.
Experts call for a coordinated approach to develop safe and effective vaccines, requiring creativity, cooperation, and commitment to save lives. Multiple successful vaccines are needed to meet the global need of immunizing billions.
The development of an effective COVID-19 vaccine is critical to preventing repeated epidemics due to the human population's naivety to the virus. A judicious approach involves evaluating candidate vaccines in healthy adults while also using animal models, with parallel process development for efficient production scale-up.
A Korean research team developed a new vaccine platform using RNA-based adjuvants for the MERS coronavirus. The platform was successfully tested on nonhuman primates with 100% protective efficacy. The researchers expect the platform to be applicable to COVID-19 vaccine development, which is urgently needed globally.
Researchers at Karolinska Institutet and the universities of Jyväskylä and Tampere have produced a vaccine that protects against all six known strains of Coxsackie B virus, which may play a role in triggering type 1 diabetes. The vaccine was tested in animal models and showed promise, with plans to conduct human clinical trials.
Researchers have developed a vaccine that protects against the Coxsackie B virus, which may play a role in triggering type 1 diabetes. The vaccine was shown to be highly immunogenic and protective in animal models and non-human primates.
A newly developed inactivated SARS-CoV-2 vaccine candidate protected macaques from infection and neutralized multiple virus strains without ADE risk. Clinical trials with the PiCoVacc are expected to begin later this year.
Researchers identified a significant fraction of antibodies expressed by B cell plasmablasts circulating after DENV infection, particularly in individuals experiencing their first infection. This finding holds promise for developing new diagnostic tools and a safe, efficacious dengue vaccine.
Researchers are testing the effectiveness of hydroxychloroquine as a preventative therapy for COVID-19 in healthy individuals who have been exposed to infected patients. The study aims to prevent infection and symptoms, with the goal of protecting vulnerable populations and reducing transmission within households.
The University of Saskatchewan's VIDO-InterVac has been awarded $23 million to fast-track COVID-19 vaccine development. The funding will support pre-clinical testing and two phases of clinical trials, with the goal of making a safe and effective vaccine available as early as next spring.
George Mason University's National Center for Biodefense and Infectious Diseases will provide expertise and resources to Emergex in developing CD8+ priming RNA virus vaccines. These vaccines offer advantages over traditional vaccines by providing a cell-mediated immune response, reducing allergic and autoimmune side effects.
A recent trial of a MERS coronavirus vaccine candidate has shown promising results, with the vaccine inducing antibody and T cell responses in nearly all trial subjects. The findings have implications for the development of a vaccine against SARS-CoV-2, with plans to conduct further trials.
The Coalition for Epidemic Preparedness Innovations (CEPI) grants $6.9 million funding to INOVIO and IVI to conduct clinical testing in Korea for INOVIO's COVID-19 vaccine candidate based on their well-established DNA platform technology. The trial will be conducted in parallel to INOVIO's Phase I INO-4800 study underway in the US.
Researchers at the University of Texas Medical Branch have created a reverse genetic system for SARS coronavirus 2, allowing for quick development and evaluation of vaccines and diagnosis of infected patients. The system enables high-throughput testing in 12 hours, significantly reducing turnaround time compared to conventional methods.
Researchers at the Butantan Institute and Boston Children's Hospital have developed a novel pneumonia vaccine capable of providing protection against all serotypes of Streptococcus pneumoniae. The vaccine is less expensive and more effective than current vaccines, with an estimated price of $2 per dose.
The Coronavirus Immunotherapy Consortium will streamline and accelerate the development of antibody therapies against SARS-CoV-2, providing crucial insights to guide vaccine development. CoVIC brings together scientists worldwide to share and evaluate candidate antibodies in a blinded analysis.
Researchers have identified two crucial surface proteins, SpyAD and Isp2, that contribute to Group A streptococcus fitness in the female genital tract. This discovery may lead to the development of effective treatments and vaccines for puerperal sepsis.